Court confirms validity of UCB’s Vimpat patent for Epilepsy

UCB has announced that in a decision released, the Court of Appeals for the Federal Circuit (CAFC) has affirmed the Delaware District Court and confirmed the validity of U.S. patent RE38,551 related to Vimpat® (lacosamide), UCB’s anti-epileptic drug.

The decision, taken by 2-1 majority, by the Court uphelp a judgement by a lower-court judge rejecting claims by Accord Healthcare, Amneal, Mylan, Sun Pharma, Apotex, Allergan and others that UCB’s patent on Vimpat should be cancelled because it was a modification of an earlier patent issued to the same inventor.

“We are pleased with the CAFC decision,” said Anna Richo UCB’s Executive Vice President and General Counsel. “This confirms the strength of our intellectual property for Vimpat® and maintains UCB’s exclusivity position until March 2022.” This decision supports UCB’s commitment to epilepsy patients and UCB’s ability to deliver Vimpat® to patients.

About Pharmascroll:

Pharmascroll is a diligent business consulting and market research firm focused solely towards pharmaceutical markets. The company consults and researches in majorly chronic disease indications prevalent across the globe. The research conducted by Pharmascroll analysts is targeted to provide analytical and logical answers to the key business questions of the pharmaceutical and medical insights teams and to make better informed business decisions with the detailed relevant information available.

To read more news about Epilepsy indication, visit https://pharmascroll.com/news-category/epilepsy/

News Source: UCB Pharma website

Image Source: https://www.adlershop.ch/p/44830/vimpat-filmtabletten-200mg-56-stueck